“Now as we move into Q2 and Q3, we will start actually shipping our vaccine into a thousand hemisphere countries where vaccination campaigns are gonna start and in particular in Brazil where we won the two-year contract for adults, which is a very important vaccination country.”

In context

“We've also set up a model where we can successfully transition the Medicare path patients out of USG and into our traditional Medicare model beginning March first of this year. And so we can't predict exactly what the timing and shape of those waves will be, but we're ready to execute against. Albert Bourla: Yeah. On the national, I will start with Comenity. Alexandre de Germay: As you know, international community is bigger than Pax COVID. Communetic, we beat consensus quite nicely with by $130 million, essentially driven by execution. As you know, in international, December is in the Q1 of 2025, so in December, we continue to execute our contract in the UK and in Europe. And in a competitive setup like in Japan, we maintain very strong leadership there until the end of the vaccination. Now as we move into Q2 and Q3, we will start actually shipping our vaccine into a thousand hemisphere countries where vaccination campaigns are gonna start and in particular in Brazil where we won the two-year contract for adults, which is a very important vaccination country. Now when we talk about the actuality, you know, actuality is smaller internationally. And we performed as we were expected. We have now a Paxlovid commercially sold in 49 markets, so there is no more advanced purchasing phenomenon. So it's really associated with utilization. The point is in international, we have actually low utilization compared to the US. We still need to do some work in terms of utilization and treatment. Thank you, Alexandre. Operator, please, the next question. Operator: We'll go next to Evan Seigerman with BMO Capital Markets. Evan Seigerman: Hi, guys. Thank you so much for taking my question. And I didn't wanna touch on the reasons for the Daniel discontinuation, but I more want to look forward. You think about a potential obesity asset. What are some key aspects o”